These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37035469)

  • 21. Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients.
    Suppan C; Steiner D; Klocker EV; Posch F; Henzinger E; Müller HD; Stöger H; Dandachi N; Balic M
    Breast Care (Basel); 2021 Dec; 16(6):607-613. PubMed ID: 35082570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
    Xu B; Zhang Q; Sun T; Li W; Teng Y; Hu X; Bondarenko I; Adamchuk H; Zhang L; Trukhin D; Wang S; Zheng H; Tong Z; Shparyk Y; Wang Q;
    BioDrugs; 2021 May; 35(3):337-350. PubMed ID: 33826080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
    Chen X; Li C; Ewesuedo R; Yin D
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
    Romond EH; Jeong JH; Rastogi P; Swain SM; Geyer CE; Ewer MS; Rathi V; Fehrenbacher L; Brufsky A; Azar CA; Flynn PJ; Zapas JL; Polikoff J; Gross HM; Biggs DD; Atkins JN; Tan-Chiu E; Zheng P; Yothers G; Mamounas EP; Wolmark N
    J Clin Oncol; 2012 Nov; 30(31):3792-9. PubMed ID: 22987084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of Treatment Safety Between Brand-Name Product and Biosimilar of Trastuzumab].
    Tatsuta R; Sumimoto T; Nakahara R; Tanaka R; Itoh H
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):945-949. PubMed ID: 34267033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.
    Ganz PA; Romond EH; Cecchini RS; Rastogi P; Geyer CE; Swain SM; Jeong JH; Fehrenbacher L; Gross HM; Brufsky AM; Flynn PJ; Wahl TA; Seay TE; Wade JL; Biggs DD; Atkins JN; Polikoff J; Zapas JL; Mamounas EP; Wolmark N
    J Clin Oncol; 2017 Dec; 35(35):3942-3948. PubMed ID: 29072977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.
    Huang F; Brezden-Masley C; Chan KKW; Barfett JJ; Kirpalani A; Deva DP; Jimenez-Juan L; Barthur A; Song L; Chacko B; Ng MY; Connelly K; Wong KCK; Yan AT
    Eur Radiol; 2022 Jun; 32(6):4234-4242. PubMed ID: 34993574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.
    Bachir B; Anouti S; Abi Jaoude J; Kayali M; Tfayli A; de Azambuja E; Poortmans P; Zeidan YH
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):135-142. PubMed ID: 34986381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.
    Wisman LA; De Cock EP; Reijers JA; Kamerling IM; Van Os SH; de Kam ML; Burggraaf J; Voortman G
    Clin Drug Investig; 2014 Dec; 34(12):887-94. PubMed ID: 25377592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
    J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
    J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
    de Azambuja E; Agostinetto E; Procter M; Eiger D; Pondé N; Guillaume S; Parlier D; Lambertini M; Desmet A; Caballero C; Aguila C; Jerusalem G; Walshe JM; Frank E; Bines J; Loibl S; Piccart-Gebhart M; Ewer MS; Dent S; Plummer C; Suter T;
    ESMO Open; 2023 Feb; 8(1):100772. PubMed ID: 36681013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns.
    Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V
    JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab.
    Alexeev SM; Khorinko AV; Mukhametshina GZ; Shelepen KG; Burdaeva ON; Kulik SA; Satheesh CT; Srivastava K; Vikranth M; Kryukov F; Paltusova AN; Shustova MS; Ivanov RA
    BMC Cancer; 2020 Aug; 20(1):783. PubMed ID: 32819305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction.
    Hussain Y; Drill E; Dang CT; Liu JE; Steingart RM; Yu AF
    Breast Cancer Res Treat; 2019 May; 175(1):239-246. PubMed ID: 30721443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial.
    Leong DP; Cosman T; Alhussein MM; Kumar Tyagi N; Karampatos S; Barron CC; Wright D; Tandon V; Magloire P; Joseph P; Conen D; Devereaux PJ; Ellis PM; Mukherjee SD; Dhesy-Thind S
    JACC CardioOncol; 2019 Sep; 1(1):1-10. PubMed ID: 34396157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
    J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.
    Cesarec A; Likić R
    Appl Health Econ Health Policy; 2017 Apr; 15(2):277-286. PubMed ID: 27730538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
    Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
    Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.